Interstitial cystitis (IC) is a common entity with significant quality of life effects. However, the exact prevalence and incidence of IC is unclear a prior attempts to address this used solely administrative claims data or referral patterns from tertiary care referral centers. In order to define the national prevalence and incidence of IC, we propose a study using nation-wide data pulled from the Veterans Affairs (VA) Medical Centers, the largest integrated health system in the country. The goals of this study are to identify every IC patient within the VA system, to dive deep into the medical records of these patients to confirm the diagnosis of IC using a combination of automated data pulls plus hand-abstraction, to determine what other comorbid conditions co-exist with IC, and to assess treatment patterns and outcomes. By normalizing these data to US nation-wide numbers, we will be able to estimate the US nation-wide incidence and prevalence of IC. We will also prospective enroll a subset of these patients in a cohort study obtaining valuable quality of life data, patient-reporte outcomes, and urine samples. From this, we will be able to better assess the impact of IC on day-to-day life of the patients. Using the urine samples, we will explore whether biomarkers we have already identified to predict IC flare can be used to confirm the diagnosis of IC.
Specific Aims are (Aim 1) Identify national-level prevalence and incidence of interstitial cystitis among a socio-economically and racially diverse population;
(Aim 2) Prospectively determine the association between interstitial cystitis and health related quality of life and other comorbid conditions through validated questionnaires;
and (Aim 3) Explore urine-based biomarkers to diagnose IC. If successful, our project has the possibility, for the first time, of clearly definin national-level prevalence and incidence of IC along with valuable information on treatment patterns and outcomes, impact of IC on quality of life and other co-morbid conditions, and even validate a biomarker for IC diagnosis. In summary, this study, by using an innovative approach to tap into nation-wide data, holds the potential to shed tremendous light on a disease of which to date we know very little.

Public Health Relevance

Our goals in this proposed study are to estimate the US nationwide prevalence and incidence of interstitial cystitis (IC) using a large, heterogeneous cohort from the Veterans Affairs healthcare system, the largest integrated health care system in the US. We will also prospectively enroll subjects to identify the impact of IC on individual healt and test the value of a specific set of urine biomarkers already identified by our research team to diagnose IC. This study will dramatically enhance our understanding of the epidemiology of IC and will be the basis for multiple prospective studies aiming to increase diagnostic accuracy, and thus has direct relevance to human health and patient care.

Agency
National Institute of Health (NIH)
Institute
National Center for Chronic Disease Prev and Health Promo (NCCDPHP)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01DP006079-03
Application #
9302282
Study Section
Special Emphasis Panel (ZDP1)
Program Officer
Law, Marcella
Project Start
2015-09-30
Project End
2020-09-29
Budget Start
2017-09-30
Budget End
2018-09-29
Support Year
3
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Cedars-Sinai Medical Center
Department
Type
DUNS #
075307785
City
Los Angeles
State
CA
Country
United States
Zip Code
90048
Ha, Yun-Sok; Kim, Yeon-Yong; Yu, Na Hee et al. (2018) Down-regulation of transient receptor potential melastatin member 7 prevents migration and invasion of renal cell carcinoma cells via inactivation of the Src and Akt pathway. Investig Clin Urol 59:263-274
Lee, Min Young; Yeon, Austin; Shahid, Muhammad et al. (2018) Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance. Oncotarget 9:13231-13243
Piao, Xuan-Mei; Byun, Young Joon; Kim, Wun-Jae et al. (2018) Unmasking molecular profiles of bladder cancer. Investig Clin Urol 59:72-82
Kim, Karen E; Randal, Fornessa; Johnson, Matt et al. (2018) Economic assessment of patient navigation to colonoscopy-based colorectal cancer screening in the real-world setting at the University of Chicago Medical Center. Cancer 124:4137-4144
Shahid, Muhammad; Gull, Nicole; Yeon, Austin et al. (2018) Alpha-oxoglutarate inhibits the proliferation of immortalized normal bladder epithelial cells via an epigenetic switch involving ARID1A. Sci Rep 8:4505
Jung, Jae Hun; You, Sungyong; Oh, Jae Won et al. (2018) Integrated proteomic and phosphoproteomic analyses of cisplatin-sensitive and resistant bladder cancer cells reveal CDK2 network as a key therapeutic target. Cancer Lett 437:1-12
Moon, Ju-Yeun; Choi, Man Ho; Kim, Jayoung (2016) Metabolic profiling of cholesterol and sex steroid hormones to monitor urological diseases. Endocr Relat Cancer 23:R455-67
Kind, Tobias; Cho, Eunho; Park, Taeeun D et al. (2016) Interstitial Cystitis-Associated Urinary Metabolites Identified by Mass-Spectrometry Based Metabolomics Analysis. Sci Rep 6:39227
Chen, Zhaohui; Kim, Jayoung (2016) Urinary proteomics and metabolomics studies to monitor bladder health and urological diseases. BMC Urol 16:11
Kim, Jayoung (2016) Immune checkpoint blockade therapy for bladder cancer treatment. Investig Clin Urol 57 Suppl 1:S98-S105

Showing the most recent 10 out of 11 publications